Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study
Indu S. Voruganti Maddali(Stanford University), Alexander V. Louie(London Health Sciences Centre), K. Franks(Leeds Teaching Hospitals NHS Trust), Kevin Lee Min Chua(National Cancer Centre Singapore), Matthew Evison(Manchester Academic Health Science Centre), Nazia Chaudhuri(University of Ulster), Tim J. Kruser(Northwestern Memorial Hospital), Stephen Harrow(Beatson West of Scotland Cancer Centre), Lorraine McLeod(NHS Greater Glasgow and Clyde), Percy Lee(City Of Hope National Medical Center), Jacqueline M. Kruser(VA Center for Clinical Management Research), Cicely Cunningham(NHS Greater Glasgow and Clyde), Iain Phillips(Western General Hospital), C. Peedell(South Tees Hospitals NHS Foundation Trust), Houda Bahig(Centre Hospitalier de l’Université de Montréal), Gregory M.M. Videtic(Cleveland Clinic), Suresh Senan(Amsterdam Neuroscience), Clifford G. Robinson(Barnes-Jewish Hospital), Shankar Siva(The University of Melbourne), David A. Palma(Western University), Angela Wright(NHS Greater Glasgow and Clyde), Susan Harden(Johns Hopkins University), Xiaotao Qu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Corinne Faivre‐Finn(University of Manchester)
Cited by 20
Related Papers
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k